Fatty liver disease has become one of the fastest-growing health problems around the world.
It is closely linked with obesity, type 2 diabetes and excess body weight. In some people, fat builds up inside the liver and triggers inflammation, causing a serious condition called metabolic dysfunction-associated steatohepatitis, or MASH.
Over time, this inflammation can leave permanent scars, known as fibrosis, and eventually lead to cirrhosis, liver failure or the need for a liver transplant.
Doctors have struggled to find effective treatments for people with advanced MASH, especially those who have already developed early cirrhosis. Once the liver becomes badly scarred, it is much harder to repair.
For many years, lifestyle changes such as weight loss, healthy eating and regular exercise have remained the main recommendations because few medicines have shown clear benefits.
A new international clinical trial now offers encouraging news. Researchers from the University of California San Diego School of Medicine reported that semaglutide, a medicine already widely used to treat type 2 diabetes and obesity, may also improve liver scarring in people with advanced MASH. The findings were published on July 15, 2026, in The Lancet Gastroenterology & Hepatology.
Semaglutide belongs to a group of medicines called GLP-1 receptor agonists. These drugs help control blood sugar, reduce appetite and often lead to weight loss. Scientists have long suspected that these effects might also improve liver health because excess weight and insulin resistance are major drivers of fatty liver disease.
The phase 2 study followed about 700 adults whose diagnosis of MASH had been confirmed with liver biopsies. Many participants already had moderate or severe liver scarring, and some had developed compensated cirrhosis, an early stage of cirrhosis where the liver can still perform most of its normal jobs.
The researchers mainly wanted to test whether combining semaglutide with an experimental medicine called zalfermin would work better than either treatment alone. Zalfermin is designed to improve metabolism in a different way from semaglutide.
The combination treatment did not produce better results than placebo. However, semaglutide by itself produced an important finding. Patients taking semaglutide showed significant improvement in liver scarring without worsening the inflammation that causes ongoing liver damage. This benefit was even seen in patients with more advanced disease.
The study also found that blood tests and imaging scans reflected treatment changes better than repeated liver biopsies. This could become important because biopsies require a needle to remove liver tissue and are uncomfortable, expensive and difficult to repeat regularly.
The researchers caution that this is not the final answer. Larger studies focusing on patients with cirrhosis are still needed to confirm whether semaglutide can slow disease progression, prevent liver failure or reduce the need for transplantation. They also believe medicines similar to zalfermin may still prove useful after further development.
Overall, this study provides hope for a group of patients who have had very limited treatment choices. Because semaglutide is already widely prescribed for diabetes and obesity, doctors already understand much of its safety profile, which could speed future clinical use if larger trials confirm the benefits. The research also highlights the growing connection between metabolic health and liver disease, suggesting that treating the underlying causes may help protect the liver as well as improve overall health.
Review and analysis: This was a well-designed international phase 2 clinical trial involving a large number of participants with biopsy-confirmed disease, making the findings more reliable than smaller studies.
However, the trial mainly shows that semaglutide improved liver fibrosis rather than proving it prevents liver failure or extends life. More phase 3 trials are needed before treatment recommendations change, but the results represent one of the strongest pieces of evidence so far that GLP-1 medicines may benefit patients with advanced MASH.
If you care about diabetes, please read studies about diabetes and vitamin B12, and the right diet for people with type 2 diabetes.
For more health information, please see recent studies about how to eat smart with diabetes, and turmeric and vitamin D: a duo for blood pressure control in diabetic patients.
Source: University of California San Diego.
